Gebo KA - Search Results

1

The shifting age distribution of people with HIV using antiretroviral therapy in the United States.

Althoff KN, Stewart CN, Humes E, Zhang J, Gerace L, Boyd CM, Wong C, Justice AC, Gebo KA, Thorne JE, Rubtsova AA, Horberg MA, Silverberg MJ, Leng SX, Rebeiro PF, Moore RD, Buchacz K, Kasaie P. Althoff KN, et al. Among authors: gebo ka. AIDS. 2022 Mar 1;36(3):459-471. doi: 10.1097/QAD.0000000000003128. AIDS. 2022. PMID: 34750289 Free PMC article.

2

Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients.

Gebo KA, Moore RD, Keruly JC, Chaisson RE. Gebo KA, et al. J Infect Dis. 1996 Apr;173(4):857-62. doi: 10.1093/infdis/173.4.857. J Infect Dis. 1996. PMID: 8603963

3

Costs of HIV medical care in the era of highly active antiretroviral therapy.

Gebo KA, Chaisson RE, Folkemer JG, Bartlett JG, Moore RD. Gebo KA, et al. AIDS. 1999 May 28;13(8):963-9. doi: 10.1097/00002030-199905280-00013. AIDS. 1999. PMID: 10371178

4

Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy.

Gebo KA, Diener-West M, Moore RD. Gebo KA, et al. J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):143-52. doi: 10.1097/00126334-200106010-00009. J Acquir Immune Defic Syndr. 2001. PMID: 11404536

5

Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic.

Lucas GM, Gebo KA, Chaisson RE, Moore RD. Lucas GM, et al. Among authors: gebo ka. AIDS. 2002 Mar 29;16(5):767-74. doi: 10.1097/00002030-200203290-00012. AIDS. 2002. PMID: 11964533

6

Association of social stress, illicit drug use, and health beliefs with nonadherence to antiretroviral therapy.

Gebo KA, Keruly J, Moore RD. Gebo KA, et al. J Gen Intern Med. 2003 Feb;18(2):104-11. doi: 10.1046/j.1525-1497.2003.10801.x. J Gen Intern Med. 2003. PMID: 12542584 Free PMC article.

7

Hospitalization rates differ by hepatitis C satus in an urban HIV cohort.

Gebo KA, Diener-West M, Moore RD. Gebo KA, et al. J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):165-73. doi: 10.1097/00126334-200310010-00006. J Acquir Immune Defic Syndr. 2003. PMID: 14526205

8

The HIV Research Network: a unique opportunity for real time clinical utilization analysis in HIV.

Gebo KA, Moore RD, Fleishman JA. Gebo KA, et al. Hopkins HIV Rep. 2003 Nov;15(6):5-6. Hopkins HIV Rep. 2003. PMID: 14974424 No abstract available.

9

Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection.

Gebo KA, Gallant JE, Keruly JC, Moore RD. Gebo KA, et al. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1028-33. doi: 10.1097/00126334-200408150-00005. J Acquir Immune Defic Syndr. 2004. PMID: 15247555

10

Treatment of HIV infection in the older patient.

Gebo KA, Moore RD. Gebo KA, et al. Expert Rev Anti Infect Ther. 2004 Oct;2(5):733-43. doi: 10.1586/14789072.2.5.733. Expert Rev Anti Infect Ther. 2004. PMID: 15482236 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

265 results

Search Page

Filters